Lercanidipina Jaba (Lercanidipine Hydrochloride)

Lercanidipine Hydrochloride blocks L-type calcium channels in the smooth muscle of arteries. This blockade prevents calcium from entering the cells, causing the vessels to relax and widen (vasodilation), which lowers peripheral resistance and consequently reduces systemic blood pressure.

The appropriate dose of Lercanidipina Jaba is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any concomitant medications. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety data for Lercanidipine Hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Both Lercanidipine and amlodipine belong to the dihydropyridine class of calcium channel blockers and lower blood pressure by vasodilation. Lercanidipine has a longer half‑life, allowing once‑daily dosing, and may be associated with a lower incidence of peripheral edema compared with amlodipine, though individual responses vary.

Store the tablets at room temperature, below 25 °C, in the original packaging. Keep them away from moisture, direct sunlight, and excessive heat to maintain product stability throughout its shelf life.

Lercanidipina Jaba is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events include severe hypotension, angioedema (rapid swelling of the face, lips, tongue, or throat), and rare cases of myocardial infarction. Patients should seek immediate medical attention if they experience sudden dizziness, fainting, swelling of the airway, or chest pain.

Lercanidipina Jaba is contraindicated in patients with known hypersensitivity to Lercanidipine or any component of the formulation. It should also be avoided in individuals with severe aortic stenosis or uncontrolled heart failure unless a specialist determines that benefits outweigh risks.